期刊文献+

我院头孢吡肟用量与常见检出菌耐药相关性分析

Correlation between consumption of cefepime and drug resistance of common clinical pathogens in our hospital
在线阅读 下载PDF
导出
摘要 目的:探讨我院头孢吡肟用量、用药频度和耐药率之间的相关性。方法:采用回顾性分析方法,对2006年1月~2007年12月间临床常见检出菌对头孢吡肟的敏感率及其医院同期该药的使用量、用药频度等进行统计分析。结果:2年中,头孢吡肟的用量在不断增加,常见检出菌对头孢吡肟的耐药率也呈增长趋势,头孢吡肟的用药频度与金黄色葡萄球菌、铜绿假单胞菌耐药率相关系数分别为r=0.624 3、r=0.800 5。结论:用药频度的增高与常见检出菌对该药耐药率的增加有一定的相关性。 Objective:To study the correlation between quantities of cefepime prescribed, Daily de- fined doses (DDDs) and the drug-resistance. Methods: The susceptible rates of clinical pathogens, the consumptions and the DDDs of cefepime from 2006 to 2007 were investigated and analyzed retrospectively by statistics. Results: The resistant rates of clinical pathogens to cefepime increased with quarters. The analysis revealed a correlation between the quality of cefepime and the resistance of Staaur ( r = 0. 624 3) and pseaer (r = 0. 800 5). Conclusions : The increase of DDDs had a significant relationship with the addition of resistant rates of clinical pathogens to cefepime.
出处 《药学与临床研究》 2009年第1期61-63,共3页 Pharmaceutical and Clinical Research
关键词 头孢吡肟 耐药率 用药频度 相关性 Cefepime Drug-resistance DDDs Correlation
  • 相关文献

参考文献6

二级参考文献28

  • 1邓国华,王爱霞.新型头孢菌素Cefepime的药理与临床研究[J].中国新药杂志,1993,2(2):7-10. 被引量:8
  • 2邢旺兴.β-内酰胺酶的基本特性及其检验方法[J].国外医药(抗生素分册),1995,16(6):408-414. 被引量:12
  • 3雷军,王浴生.头孢吡肟[J].国外医药(抗生素分册),1996,17(5):354-358. 被引量:15
  • 4汪复.β-内酰胺类抗生素临床应用进展[J].中国新药杂志,1996,5(2):81-85. 被引量:22
  • 5[3]Steward CD, Rasheed J K, Hubert SK. Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extendedspectrum beta-lactamase detection methods. J Clin Microbiol.2001 ;39: 2864~2872.
  • 6[4]Coudron PE, Moland ES, Thomson KS. Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center. J Clin Microbiol, 2000;38:1791 ~ 1796.
  • 7[5]National Committee for Clinical Laboratory Standards.Performance standards for antimicrobial susceptibility testing.Ninth Informational Supplement. NCCLS Documents M 100-S9.Pennsylvania: NCCLS, 1999, 17~99.
  • 8[6]Hancock RE,Bellido F. Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins[J].J Antimicrob Chemother, 1992, 29(Suppl A) : 1-6
  • 9Murray PR , Baron EJ, Pfaller MA, et al. Manual of Clinical microbiology 7th ed. American society for microbiology, Washington, D.C.1999, 262-560.
  • 10National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 12th inform suppl. M2-A7 and M7-A5.National Committee for Clinical Laboratory Standards, Wayne, pa, 2002, 42-49.

共引文献89

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部